Comparison of anticonvulsive and acute neuroprotective activity of three 2,3-benzodiazepine compounds, GYKI 52466, GYKI 53405, and GYKI 53655

@article{Szabados2001ComparisonOA,
  title={Comparison of anticonvulsive and acute neuroprotective activity of three 2,3-benzodiazepine compounds, GYKI 52466, GYKI 53405, and GYKI 53655},
  author={T. Szabados and G. Gigler and I. Gacs{\'a}lyi and I. Gyertyán and G. L{\'e}vay},
  journal={Brain Research Bulletin},
  year={2001},
  volume={55},
  pages={387-391}
}
GYKI 52466 [1-(4-aminophenyl)-4-methyl-7,8-methylenedioxy-5H-2,3-benzodiazepine], a non-competitive AMPA [alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionate] and kainate receptor antagonist and its two analogues, GYKI 53405 [1-(4-aminophenyl)-3-acetyl-4-methyl-3,4-dihydro-7,8-methylenedioxy-5H-2,3-benzodiazepine] and GYKI 53655 [1-(4-aminophenyl)-3-methylcarbamyl-4-methyl-3,4-dihydro-7,8-methylenedioxy-5H-2,3-benzodiazepine] were investigated in two seizure models and in MgCl2 induced global… Expand
View on Elsevier
doi.org
42 Citations
Highly Influential Citations
2
Background Citations
15
Methods Citations
3

42 Citations

Citation Type

Citation Type

Protective effect of the antiepileptic drug candidate talampanel against AMPA-induced striatal neurotoxicity in neonatal rats
  • 22
Structure-activity study of 2,3-benzodiazepin-4-ones noncompetitive AMPAR antagonists: identification of the 1-(4-amino-3-methylphenyl)-3,5-dihydro-7,8-ethylenedioxy-4H-2,3-benzodiazepin-4-one as neuroprotective agent.
  • 21
Synthesis and evaluation of pharmacological properties of novel annelated 2,3-benzodiazepine derivatives.
  • 35
Effect of two noncompetitive AMPA receptor antagonists GYKI 52466 and GYKI 53405 on vigilance, behavior and spike–wave discharges in a genetic rat model of absence epilepsy
  • 31
Reduction of cerebral infarct size by non-competitive AMPA antagonists in rats subjected to permanent and transient focal ischemia
  • 27
New 7,8-ethylenedioxy-2,3-benzodiazepines as noncompetitive AMPA receptor antagonists.
  • 21
The effects of AMPA receptor antagonists in models of stroke and neurodegeneration.
  • 37
Blockade of AMPA-receptors attenuates 4-aminopyridine seizures, decreases the activation of inhibitory neurons but is ineffective against seizure-related astrocytic swelling
  • 17
  • PDF
Comparison of the AMPA Antagonist Action of New 2,3-Benzodiazepines in Vitro and Their Neuroprotective Effects in Vivo
  • 14
SYNTHESE DE NOUVELLES 1,5-BENZODIAZEPINES ASSOCIANT DIFFERENTS HETEROCYCLES A CINQ CHAINONS
  • 8
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 23 REFERENCES
GYKI 52466 and related 2,3-benzodiazepines as anticonvulsant agents in DBA/2 mice.
  • 66
Non-N-methyl-D-aspartate receptor antagonism by 3-N-substituted 2,3-benzodiazepines: relationship to anticonvulsant activity.
  • 93
  • PDF
The anticonvulsant effect of the non-NMDA antagonists, NBQX and GYKI 52466, in mice
  • 180
The neuroprotective and hypothermic effect of GYKI-52466, a non-competitive α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid-antagonist on histological and behavioural variables in the gerbil global ischemia model
  • 26
Stereoselective Effects of 2,3-benzodiazepines In Vivo: Electrophysiology and Neuroprotection Studies
  • 64
GYKI 52466, a 2,3-benzodiazepine, is a highly selective, noncompetitive antagonist of AMPA/kainate receptor responses
  • 344
  • PDF
Anticonvulsant actions of DS 103–282: Pharmacological studies in rodents and the baboon, Papio papio
  • 50
Cerebroprotective Effect of a Non–N‐Methyl‐D‐Aspartate Antagonist, GYKI 52466, After Focal Ischemia in the Rat
  • 142
Effects of the non‐NMDA antagonists NBQX and the 2,3‐benzodiazepine GYKI 52466 on different seizure types in mice: comparison with diazepam and interactions with flumazenil
  • 65
Activity of 2,3-benzodiazepines at Native Rat and Recombinant Human Glutamate Receptors In Vitro: Stereospecificity and Selectivity Profiles
  • 183
...
1
2
3
...